Marina et al. revealed that the amalgamation of US risk-stratification systems and molecular testing (e.g. v-raf murine sarcoma viral oncogene homolog B [BRAF] and rat sarcoma [RAS] mutation analyses) enhances the evaluation of malignancy risk in TBSRTC IV thyroid nodules in contrast to singular assessments.64 Here, BRAF is linked to thyroid nodule.